Atomoxetine treatment of ADHD in children with comorbid tourette syndrome

Journal of Attention Disorders

Volumn 11, Issue 4, 2008, Pages 470-481

  Spencer, Thomas J ^a   Sallee, F Randy ^b   Gilbert, Donald L ^b   Dunn, David W ^c   McCracken, James T ^d   Coffey, Barbara J ^e   Budman, Cathy L ^f   Ricardi, Randall K ^g   Leonard, Henrietta L ^h   Allen, Albert J ⁱ   Milton, Denai R ⁱ   Feldman, Peter D ⁱ   Kelsey, Douglas K ⁱ   Geller, Daniel A ^j   Linder, Steven L ^k   Lewis, Donald W ^l   Winner, Paul K ^m   Kurlan, Roger M ⁿ   Mintz, Mark ^o  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Cincinnati Children's Hospital   (United States)

^c INDIANA UNIVERSITY   (United States)

^d Neuropsychiatric Institute   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g Arizona Family Resource and Counseling Center   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j MCLEAN HOSPITAL   (United States)

^k Dallas Pediatric Neurology Associates   (United States)

^l Monarch Research Associates   (United States)

^m Premiere Research Institute   (United States)

ⁿ UNIVERSITY OF ROCHESTER   (United States)

^o Clinical Research Center of New Jersey   (United States)

more..

Author keywords

ADHD; Atomoxetine; Tic disorders; Tourette syndrome

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ATOMOXETINE; PROPYLAMINE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GILLES DE LA TOURETTE SYNDROME; HOSPITALIZATION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PROPYLAMINES; SEVERITY OF ILLNESS INDEX; TOURETTE SYNDROME;

EID: 37249077627     PISSN: 10870547     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087054707306109     Document Type: Article

References (43)

1. Allen, A.J., Kurlan, R.M., Gilbert, D.L., Linder, S.L., Lewis, D.W., Winner, P.K., et al. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941-1949.
2. Bymaster, F.P., Katner, J., Nelson, D.L., Hemrick-Luecke, S.K., Threlkeld, P.G., Heiligenstein, J.H., et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27, 699-711.
3. Castellanos, F.X., Giedd, J.N., Elia, J., Marsh, W.L., Ritchie, G.F., Hamburger, S.D., et al. (1997). Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: Effects of stimulant and dose. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 589-596.
4. Chappell, P.B., Riddle, M.A., Scahill, L., Lynch, K.A., Schultz, R., Arnsten, A., et al. (1995). Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1140-1146.
5. Cohen, D.J., Leckman, J.F., & Shaywitz, B.A. (1983). The Tourette's syndrome and other tics. In D. Shaffer, A. A. Erhardt, & L. Greenhill (Eds.), Diagnosis and treatment in pediatric psychiatry (pp. 3-28). New York: MacMillan Free Press.
6. Comings, D.E. (2001). Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Annals of the New York Academy of Sciences, 931, 50-83.
7. Comings, D.E., & Comings, B.G. (1984). Tourette's syndrome and attention deficit disorder with hyperactivity: Are they genetically related? Journal of the American Academy of Child and Adolescent Psychiatry, 23, 138-146.
8. Cummings, D.D., Singer, H.S., Krieger, M., Miller, T.L., & Mahone, E.M. (2002). Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: A pilot study. Clinical Neuropharmacology, 25, 325-332.
9. DuPaul, G.J., Power, T.J., Anastopoulos, A.D., & Reid, R. (1998). ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations. New York: Guilford.
10. Gadow, K.D., Sverd, J., Sprafkin, J., Nolan, E.E., & Grossman, S. (1999). Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry, 56, 330-336.
11. Gaffney, G.R., Perry, P.J., Lund, B.C., Bever-Stille, K.A., Arndt, S., & Kuperman, S. (2006). Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 330-336.
12. Gilbert, D.L., Batterson, J.R., Sethuraman, G., & Sallee, F.R. (2004). Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 206-214.
13. Golden, G.S. (1977). The effect of central nervous system stimulants on Tourette syndrome. Annals of Neurology, 2, 69-70.
14. Guy, W. (1976). ECDEU assessment manual for psychopharmacology (Revised Publication No. ADM 76-338). Bethesda, MD: United States Department of Health, Education, and Welfare.
15. Heil, S.H., Holmes, H.W., Bickel, W.K., Higgins, S.T., Badger, G.J., Laws, H.F., et al. (2002). Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug and Alcohol Dependence, 67, 149-156.
16. Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P., et al. (1997). Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 980-988.
17. Kelsey, D.K., Sumner, C.R., Casat, C.D., Coury, D.L., Quintana, H., Saylor, K.E., et al. (2004). Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics, 114, e1 - e8.
18. Kratochvil, C.J., Heiligenstein, J.H., Dittmann, R., Spencer, T., Biederman, J., Wernicke, J.F., et al. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 776-784.
19. Law, S.F., & Schachar, R.J. (1999). Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? Journal of the American Academy of Child and Adolescent Psychiatry, 38, 944-951.
20. Leckman, J.F., Hardin, M.T., Riddle, M.A., Stevenson, J., Ort, S.I., & Cohen, D.J. (1991). Clonidine treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry, 48, 324-328.
21. Leckman, J.F., Riddle, M.A., Hardin, M.T., Ort, S.I., Swartz, K.L., Stevenson, J., et al. (1989). The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 566-573.
22. Ledbetter, M. (2005). Atomoxetine use associated with onset of a motor tic. Journal of Child and Adolescent Psychiatric Nursing, 15, 331-333.
23. Lee, T.S.W., Lee, T.D., Lombroso, P.J., & King, R.A. (2004). Atomoxetine and tics in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 1068-1069.
24. Lowe, T.L., Cohen, D.J., Detlor, J., Kremenitzer, M.W., & Shaywitz, B.A. (1982). Stimulant medications precipitate Tourette's syndrome. Journal of the American Medical Association, 247, 1168-1169.
25. Messiha, F.S., & Knopp, W. (1976). A study of endogenous dopamine metabolism in Gilles de la Tourette's disease. Diseases of the Nervous System, 37, 470-473.
26. Meyerhoff, J.L., & Snyder, S.H. (1973). Gilles de la Tourette's disease and minimal brain dysfunction: Amphetamine isomers reveal catecholamine correlates in an affected patient. Psychopharmacologia, 29, 211-220.
27. Michelson, D., Allen, A.J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., et al. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
28. Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F.R., et al. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108, e83.
29. Physician's Desk Reference. (2005). Physician's desk reference. Montvale, NJ: Thomson Healthcare.
30. Pollack, M.A., Cohen, N.L., & Friedhoff, A.J. (1977). Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy. Archives of Neurology, 34, 630-632.
31. Poznanski, E.O., & Mokros, H.B. (1999). Children's Depression Rating Scale, Revised (CDRS-R) (2 nd ed.). Los Angeles: Western Psychological Services.
32. Riddle, M.A., Lynch, K.A., Scahill, L., deVries, A., Cohen, D.J., & Leckman, J.F. (1995). Methylphenidate discontinuation and reinitiation during long-term treatment of children with Tourette's disorder and attention-deficit hyperactivity disorder: A pilot study. Journal of Child and Adolescent Psychopharmacology, 5, 205-214.
33. Sandyk, R., & Bamford, C.R. (1988). Beneficial effects of imipramine on Tourette's syndrome. International Journal of Neuroscience, 39, 27-29.
34. Scahill, L., Chappell, P.B., Kim, Y.S., Schultz, R.T., Katsovich, L., Shepherd, E., et al. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry, 158, 1067-1074.
35. Scahill, L., Leckman, J.F., Schultz, R.T., Katsovich, L., & Peterson, B.S. (2003). A placebo-controlled trial of risperidone in Tourette syndrome. Neurology, 60, 1130-1135.
36. Scahill, L., Riddle, M.A., McSwiggin-Hardin, M., Ort, S.I., King, R.A., Goodman, W.K., et al. (1997). Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 844-852.
37. Spencer, T., Biederman, J., Coffey, B., Geller, D., Crawford, M., Bearman, S.K., et al. (2002 a). A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 59, 649-656.
38. Spencer, T., Biederman, J., Kerman, K., Steingard, R., & Wilens, T. (1993 a). Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 354-360.
39. Spencer, T., Biederman, J., Wilens, T., Steingard, R., & Geist, D. (1993 b). Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 205-210.
40. Spencer, T., Heiligenstein, J.H., Biederman, J., Faries, D.E., Kratochvil, C.J., Conners, C.K., et al. (2002 b). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63, 1140-1147.
41. Starke, K., Endo, T., & Taube, H.D. (1975). Relative pre- and post-synaptic potencies of alpha-adrenoceptor agonists in the rabbit pulmonary artery. Naunyn Schmiedeberg's Archives of Pharmacology, 291, 55-78.
42. Sverd, J. (2000). Methylphenidate treatment for children with attention deficit hyperactivity disorder and tics: Inadvisable or indispensable. In L. L. Greenhill & B. B. Osman, (Eds.), Ritalin: Theory and practice, (2 nd ed., pp. 301-320). Larchmont, NY: Mary Ann Liebert.
43. Tourette's Syndrome Study Group. (2002). Treatment of ADHD in children with tics: A randomized controlled trial. Neurology, 58, 527-536.